Quantcast
Last updated on April 18, 2014 at 10:39 EDT

Latest ImClone Systems Stories

2013-10-23 08:29:10

INDIANAPOLIS, Oct. 23, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has assigned Priority Review to the regulatory submission for ramucirumab (IMC-1121B) as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy. "We are very pleased that the FDA has granted Priority Review to ramucirumab in advanced gastric cancer, as patients with this...

2013-10-15 00:20:32

New Members Provide strong financing and operating experience TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Oct. 15, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP), announced today that Rene Lerer, M.D., Executive Chairman of Magellan Health Services (NASDAQ: MGLN), and Daniel Kazado, Senior Advisor to Melini Capital, have agreed to join the Company's Board of Directors. Dr. Lerer and Mr. Kazado replace Pierre Albouy and Herve de Kergrohen,...

2013-03-21 16:24:59

Hematology / oncology industry expert to lead promising development pipeline BOULDER, Colo., March 21, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, today announced the appointment of Michael N. Needle, M.D., to the position of Chief Medical Officer. Dr. Needle, a board certified hematologist / oncologist, will...

2012-07-24 02:29:02

NEW YORK, July 24, 2012 /PRNewswire/ -- Carl Icahn today issued the following open letter to shareholders of Forest Laboratories, Inc.: CARL C. ICAHN767 Fifth Avenue, 47(th) FloorNew York, NY 10153 July 24, 2012 Dear Fellow Forest Labs Shareholders, The Forest Labs Annual Meeting will take place on August 15, 2012. Today we mailed you our definitive proxy statement containing important information, including information on how to vote your Forest shares. Your vote is important as the...

2012-07-06 10:21:58

HILDEN, Germany, and GERMANTOWN, Maryland, July 6, 2012 /PRNewswire/ -- - U.S. launch of therascreen(R)KRAS RGQ PCR Kit offers enhanced approach to guide treatments for approximately 110,000 patients annually in U.S. with colorectal cancer - First FDA approval of a QIAGEN companion diagnostic marks a milestone in its global expansion of rapidly growing Personalized Healthcare business - Important cancer assay adds...

2012-07-02 10:22:51

NEW YORK, July 2, 2012 /PRNewswire/ -- Carl Icahn today issued the following letter to Howard Solomon, Chairman, CEO and President of Forest Laboratories, Inc.: CARL C. ICAHN767 Fifth Avenue, 47th FloorNew York, NY 10153 July 2, 2012 Via Email and Federal ExpressHoward SolomonChairman, CEO and PresidentForest Laboratories, Inc.909 Third AvenueNew York, NY 10022 Your recent statement is rife with inconsistencies, misstatements and doublespeak. I find your statement that we are...

2012-03-26 02:25:18

NEW YORK, March 26, 2012 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) today announced the appointment of Jennifer Simpson, Ph.D., M.S.N., C.R.N.P., to the position of Executive Vice President, Global Marketing. In this role, Ms. Simpson will be responsible for leading the Company's global product marketing, brand management and reimbursement programs in the European Union, United States and other key markets. Concurrent with this appointment, Agustin Gago, Delcath's Executive Vice...

2012-02-08 08:51:00

BOONTON, N.J., Feb. 8, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), today announced the expansion of its Biotechnologies strategic business unit (SBU) with the promotion of Gregory T. Mayes, Esq. to the position of Chief Business Officer and the appointment of Jane Pepper, M.B.A, Ph.D. to Senior Director, Business Development. Mr. Mayes' promotion to Chief Business Officer extends a successful tenure at Unigene since his appointment to Vice President, Corporate...

2012-01-09 07:30:00

NEW YORK, Jan. 9, 2012 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology therapeutics that target cancer stem cells (CSCs), today announced that Eric K. Rowinsky, M.D. will join the Company as Executive Vice President, Chief Medical Officer and Head of Research and Development. Dr. Rowinsky will oversee the development and registration efforts for the Company's two clinical stage drug candidates, SL-401 and SL-701, as well as its...

2011-09-12 12:15:00

EAST BRUNSWICK, N.J., Sept. 12, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced the appointment of Kenneth J. Zuerblis as Executive Vice President & Chief Financial Officer, effective today. Mr. Zuerblis brings over 30 years of financial and operational experience to Savient and will be responsible for all financial, accounting and investor relations functions of the company. Mr. Zuerblis will report directly to John H. Johnson, Chief Executive...